An Open Study on the Safety, Tolerability, and Immunogenicity of Sputnik Light Vaccine
An Open Study on the Safety, Tolerability, and Immunogenicity of Sputnik Light t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso
Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Listed as NCT04713488, this PHASE1/PHASE2 trial focuses on COVID-19 Prevention and remains ongoing. Sponsored by Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation, it has been updated 7 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Oct 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Mar 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Russian Direct Investment Fund
For direct contact, visit the study record on ClinicalTrials.gov .